FDA Clears Palatin Technologies' IND Filing To Commence Clinical Studies For Asthma
Palatin Technologies, Inc. (NYSE Amex: PTN) announced that the U.S. Food and Drug Administration (FDA) has cleared Palatin's request to begin a Phase 2A proof-of-concept human trial under an Investigational New Drug (IND) application using a subcutaneously administered formulation of PL-3994, an NPR-A agonist compound, in development for treatment of acute exacerbations of asthma. "We are ...